Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sylvie Meyer Reigner"'
Publikováno v:
American Journal of Kidney Diseases. 81:684-694.e1
The optimum starting dose of intravenous continuous erythropoietin receptor activator (C.E.R.A.) has been previously determined; this study ascertains the optimum starting dose of subcutaneous (SC) C.E.R.A. administration in pediatric patients.Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28d38bd3d5405e1efec788d484eeb076
https://doi.org/10.1053/j.ajkd.2022.11.006
https://doi.org/10.1053/j.ajkd.2022.11.006
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS The Phase II study DOLPHIN (NH19707; NCT00717366) demonstrated that pediatric patients with chronic kidney disease (CKD) on hemodialysis can be safely and effectively switched from maintenance treatment with epoetin alfa/beta or d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1590ae3d8eb93d4ad98cee5744ae3ce
https://doi.org/10.1093/ndt/gfac103.001
https://doi.org/10.1093/ndt/gfac103.001
Autor:
Franz Schaefer, Laura Benner, Anja Sander, Loes Rutten-Jacobs, Yap Hui Kim, Karel Vondrak, Paula A Coccia, Francisco Cano, Sylvie Meyer Reigner, Milena Studer
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Continuous erythropoietin receptor activator—methoxy polyethylene glycol epoetin beta (C.E.R.A.) is a long-acting erythropoiesis-stimulating agent (ESA) approved for the treatment of anaemia associated with chronic kidney diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f49daec31a66bb356634750cb402eec
https://doi.org/10.1093/ndt/gfac089.018
https://doi.org/10.1093/ndt/gfac089.018
Autor:
Arlette Weichert, Bruno Reigner, Mark D. Eisner, Bradley A. Warady, Pascal Chanu, Franz Schaefer, Nicolas Frey, Claus Peter Schmitt, Gabriel Schnetzler, Sylvie Meyer Reigner
Publikováno v:
Br J Clin Pharmacol
AIMS: Methoxy polyethylene glycol‐epoetin beta (continuous erythropoietin receptor activator, C.E.R.A.) is used for the treatment of anaemia in adults with chronic kidney disease (CKD). Patients treated with shorter‐acting erythropoiesis‐stimul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a90ea3a50fb2246530c5772aee0168f
https://doi.org/10.1111/bcp.14186
https://doi.org/10.1111/bcp.14186
Background and objectives The study was conducted to identify a conversion factor for switching from previous erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator–methoxy polyethylene glycol-epoetin beta (C.E.R.A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ded0fefbdfb7fc271e3ec414c9c6f7c0
https://europepmc.org/articles/PMC5753305/
https://europepmc.org/articles/PMC5753305/
Autor:
A. Michael Lincoff, Markolf Hanefeld, Matthias Herz, Sylvie Meyer Reigner, Nadejda Mudie, Giancarlo Viberti, Klas Malmberg, Luis M. Ruilope, Teresa Urbanowska
Publikováno v:
Atherosclerosis. 231:e3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c800b6f5a8153c38dab32eb000ccc6a
https://doi.org/10.1016/j.atherosclerosis.2013.07.015
https://doi.org/10.1016/j.atherosclerosis.2013.07.015
Publikováno v:
Journal of the American College of Cardiology. 59:E1661
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c3a236f5467b01dda68ed5a5348d255
https://doi.org/10.1016/s0735-1097(12)61662-3
https://doi.org/10.1016/s0735-1097(12)61662-3
Autor:
Markolf Hanefeld, Klas Malmberg, A. Michael Lincoff, Nadejda Mudie, Sylvie Meyer-Reigner, Dominika Wieczorek Kirk, Luis M. Ruilope, Giancarlo Viberti, Matthias Herz
Publikováno v:
BMC Nephrology
Background Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality. This Phase IIb safety study (AleNephro) in patients with stage 3 chronic kidney disease and type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::140b5ac3c75faa05d86c47379cdfb5d8
Autor:
Dubois C; Sylvie Meyer Reigner, PRBD-M, 68/217b, Hoffmann-La Roche, 4070 Basel, Switzerland., Steiner B, Meyer Reigner SC
Publikováno v:
Thrombosis and haemostasis [Thromb Haemost] 2004 Apr; Vol. 91 (4), pp. 733-42.